Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who…
adminApril 17, 2024
Keep up to date with all of our latest news and events
Use the filters to find Publications, Featured News, Clinical Trials and more.
The exceptional six-month data from Xeltis’ first-in-human (FIH) aXess conduit trial has been published in the Journal of Vascular Access.…
Content TeamFebruary 8, 2024
aXess demonstrated exceptional patency rates and no infections to date Xeltis, a leading developer of transformative implants that enable the…
Content TeamNovember 17, 2023
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces the…
Content TeamSeptember 12, 2023
Funding extends Xeltis’ Series D2 financing round to €44.5 million. Xeltis a leading developer of transformative implants that enable the…
Content TeamAugust 15, 2023
Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device,…
Content TeamJune 19, 2023
Xeltis’ restorative vascular access graft, aXess, has been successfully implanted in the first patient in Poland, as part of the…
Content TeamJune 19, 2023
aXess, Xeltis’ restorative vascular access graft for hemodialysis, has been successfully implanted in the first patient in Greece, as part…
Content TeamMay 17, 2023
aXess graft demonstrated excellent patency, low rates of infection and re-intervention Data indicates a significant improvement in performance compared to…
Content TeamApril 28, 2023
New investors DaVita Venture Group and Invest-NL join syndicate of international investors, including Grand Pharma and EQT Life Sciences, investing…
Content TeamFebruary 21, 2023
The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh,…
Content TeamNovember 30, 2022
Professor Frans Moll, University Medical Center Utrecht, will update an audience of international vascular surgeons at the VEITH Symposium in…
Content TeamNovember 18, 2022
Dr An de Vriese, who is playing a leading role in the ongoing European pivotal trial investigating the aXess vascular…
Content TeamNovember 17, 2022
Xeltis has started the pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have…
Content TeamNovember 10, 2022
Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device,…
Content TeamNovember 9, 2022
The Chinese company Grand Pharmaceutical Group Ltd (0512.HK) has committed to invest €15 million in equity and license fees, as…
Content TeamAugust 9, 2022
The protocol for our ongoing Pivotal Study for the aXess hemodialysis graft has been published in the Journal of Vascular…
Content TeamMay 30, 2022
Results from novel imaging analysis of the Endogenous Tissue Restoration (ETR) process in Xeltis’ devices further advance the understanding of…
Content TeamMay 3, 2022
Renal Interventions dedicated a feature article to arteriovenous grafts (AVG) for hemodialysis access, in which Xeltis’ restorative AVG graft aXess…
Content TeamApril 8, 2022
Xeltis’ devices are the first living applications of supramolecular materials for cardiovascular restoration in patients. An article published in peer-reviewed…
Content TeamApril 5, 2022
Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared…
Content TeamMarch 11, 2022
Matteo Tozzi, MD, vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD,…
Content TeamJanuary 12, 2022
Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission.…
Content TeamDecember 21, 2021
The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will…
Content TeamNovember 22, 2021
The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living…
adminOctober 14, 2021
Xeltis’ polymers have shown superior pro-healing response and no calcification compared to conventional biological heart valve devices in preclinical trial…
adminAugust 6, 2021
Promising early outcomes from two clinical trials of Xeltis pulmonary valve confirm the excellent safety and performance of its bio-restorative…
adminMarch 12, 2021
Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve…
adminFebruary 25, 2021
Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The…
adminSeptember 5, 2019
Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to…
adminMarch 8, 2019
Renal Interventions dedicated a feature article to arteriovenous grafts (AVG) for hemodialysis access, in which Xeltis’ restorative AVG graft aXess…
Content TeamApril 8, 2022
Matteo Tozzi, MD, vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD,…
Content TeamJanuary 12, 2022
Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who…
adminApril 17, 2024
aXess demonstrated exceptional patency rates and no infections to date Xeltis, a leading developer of transformative implants that enable the…
Content TeamNovember 17, 2023
Professor Frans Moll, University Medical Center Utrecht, will update an audience of international vascular surgeons at the VEITH Symposium in…
Content TeamNovember 18, 2022
Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve…
adminFebruary 25, 2021
The exceptional six-month data from Xeltis’ first-in-human (FIH) aXess conduit trial has been published in the Journal of Vascular Access.…
Content TeamFebruary 8, 2024
The protocol for our ongoing Pivotal Study for the aXess hemodialysis graft has been published in the Journal of Vascular…
Content TeamMay 30, 2022
Results from novel imaging analysis of the Endogenous Tissue Restoration (ETR) process in Xeltis’ devices further advance the understanding of…
Content TeamMay 3, 2022
Xeltis’ devices are the first living applications of supramolecular materials for cardiovascular restoration in patients. An article published in peer-reviewed…
Content TeamApril 5, 2022
The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living…
adminOctober 14, 2021
Xeltis’ polymers have shown superior pro-healing response and no calcification compared to conventional biological heart valve devices in preclinical trial…
adminAugust 6, 2021
Promising early outcomes from two clinical trials of Xeltis pulmonary valve confirm the excellent safety and performance of its bio-restorative…
adminMarch 12, 2021
Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to…
adminMarch 8, 2019
New investors DaVita Venture Group and Invest-NL join syndicate of international investors, including Grand Pharma and EQT Life Sciences, investing…
Content TeamFebruary 21, 2023
The Chinese company Grand Pharmaceutical Group Ltd (0512.HK) has committed to invest €15 million in equity and license fees, as…
Content TeamAugust 9, 2022
Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission.…
Content TeamDecember 21, 2021
The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will…
Content TeamNovember 22, 2021
Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The…
adminSeptember 5, 2019
aXess demonstrated exceptional patency rates and no infections to date Xeltis, a leading developer of transformative implants that enable the…
Content TeamNovember 17, 2023
Xeltis’ restorative vascular access graft, aXess, has been successfully implanted in the first patient in Poland, as part of the…
Content TeamJune 19, 2023
aXess, Xeltis’ restorative vascular access graft for hemodialysis, has been successfully implanted in the first patient in Greece, as part…
Content TeamMay 17, 2023
The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh,…
Content TeamNovember 30, 2022
Dr An de Vriese, who is playing a leading role in the ongoing European pivotal trial investigating the aXess vascular…
Content TeamNovember 17, 2022
Xeltis has started the pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have…
Content TeamNovember 10, 2022
Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device,…
Content TeamNovember 9, 2022
Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared…
Content TeamMarch 11, 2022
Press Releases
Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft
Media
ETR Powered Platform
Endogenous Tissue Restoration Animation
Pulmonary Heart Valve
Endogenous Tissue Restoration Animation
Prof. Mauro Gargiulo
The aXess EU Pivotal Trial
Professor Thierry Carrel
Xeltis’ technology
Martijn Cox
Xeltis’ Co-founder on ETR
Professor Jean-Marie Lehn
Nobel Laureate Professor Lehn visits Xeltis
A Patient’s Perspective
An interview with Stefan
Global Impact of Heart Valve Disease
Professor Christian M. Spaulding
